Nanoscope Therapeutics announced that co-founder, President, and Chief Scientific Officer Samarendra Mohanty will present an Innovation Spotlight at the Cell & Gene Meeting on the Mesa 2026 in Phoenix on October 6. Mohanty will provide an update on the company’s progress toward potential global approval of MOGENRY (MCO-010), an investigational optogenetic therapy for inherited retinal diseases, including the status of its Biologics License Application currently under FDA review. The presentation is part of the October 5–7 conference organized by the Alliance for Regenerative Medicine, which brings together companies, investors, researchers, and other participants in the cell and gene therapy sector.
